Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia

Robak, Tadeusz, Kazmierczak, Maciej, Jarque, Isidro, Musteata, Vasile, Trelinski, Jacek, Cooper, Nichola, Kiessling, Peter, Massow, Ute, Woltering, Franz, Snipes, Rose, Ke, Juan, Langdon, Grant, Bussel, James B. and Jolles, Stephen 2020. Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia. Blood Advances 4 (17) , pp. 4136-4146. 10.1182/bloodadvances.2020002003

PDF - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (0B)

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Additional Information:	PDF added in accordance with the publisher's policies at http://v2.sherpa.ac.uk/id/publication/32010 (accesses 7/9/20)//
Publisher:	American Society of Hematology
ISSN:	2473-9529
Funders:	N/A
Date of First Compliant Deposit:	7 September 2020
Date of Acceptance:	15 July 2020
Last Modified:	16 Sep 2021 11:00
URI:	https://orca.cardiff.ac.uk/id/eprint/134675

Citation Data

Cited 63 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item